Araceli Biosciences Closes $4.5M to Expand Product Offerings
Araceli Biosciences closed $4.5M in financing with investor Jeff Swickard to expand commercial product offerings and develop consumables.
The big picture: Araceli Biosciences, an Oregon-based developer of cellular imaging technology for drug discovery, has closed a $4.5 million financing round, adding investor Jeff Swickard as it prepares to expand its commercial product offerings.
Why it matters:
- Accelerated Drug Discovery: The funding supports the continued commercialization of Araceli’s Endeavor cellular imaging platform, which helps pharmaceutical and biotechnology researchers monitor cellular responses to experimental drug compounds.
- Ethical Research Advancement: The Endeavor platform facilitates the adoption of New Approach Methodologies (NAMs), utilizing human cell-based assays to evaluate drug safety and effectiveness, thereby reducing reliance on traditional animal testing.
- Industry Adoption: Araceli’s systems are currently deployed by 10 of the world’s 20 largest pharmaceutical companies, demonstrating significant market penetration and trust in its technology.
How it works:
- AI-Driven Imaging: Araceli develops high-performance imaging systems integrated with artificial intelligence-driven analysis software, enabling precise monitoring of cellular responses.
- Early Data Insights: The technology is designed to help researchers collect and analyze biological data earlier in the drug development process, improving efficiency and decision-making.
- Consumable Product Expansion: The company is entering a second phase of commercialization, introducing consumable products optimized for its existing customer base to support broader use of its technology in research laboratories.
The catch: While the company projects significant revenue growth, specific financial figures, valuation, and the individual investment amounts of other participants in the financing round were not disclosed, limiting a comprehensive financial assessment. The broader rollout of new consumable products is planned for 2027, indicating a longer-term horizon for this commercial expansion.
Key Facts
- Company: Araceli Biosciences
- Amount: $4.5M
- Investor: Jeff Swickard (lead)
- Sector: Cellular Imaging Technology for Drug Discovery
- Headquarters: Tigard, Oregon, US
AIPressRoom Weekly
Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.